Back
Genmab AS Quote, Financials, Valuation and Earnings
Sponsored
GMAB
Sponsored
FREE REPORT: 2025 Gold Price Outlook
Get Your Copy of "2025 Gold Forecast: A Perfect Storm for Demand" Here.
Sell
19
GMAB
Genmab AS
Last Price:
$20.31
Seasonality Move:
3.07%
7 Day Trial
ALL ACCESS PASS
$
7
This Tech Company Grew 32,481%...
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.Genmab AS Price Quote
$20.31
+0.00 (+1.1%)
(Updated: December 21, 2024 at 5:28 AM ET)
Genmab AS Key Stats
Sell
19
Genmab AS (GMAB)
is a Sell
Day range:
$20.13 - $20.43
52-week range:
$19.85 - $32.88
Dividend yield:
0%
P/E ratio:
21.18
P/S ratio:
4.58
P/B ratio:
2.7%
Volume:
1.8M
Avg. volume:
1.3M
1-year change:
-33.56%
Market cap:
$12.9B
Revenue:
$2.4B
EPS:
$1.05
How Much Does Genmab AS Make?
Data Unavailable
Is Genmab AS Growing As A Company?
Data Unavailable
Genmab AS Stock Price Performance
What Is Genmab AS 52-Week High & Low?
Genmab AS Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Genmab AS?
Data Unavailable
Is Genmab AS Cash Flow Positive?
Data Unavailable
Genmab AS Return On Invested Capital
Data Unavailable
Genmab AS Earnings Date & Stock Price
-
What Is Genmab AS's Stock Price Today?A single share of GMAB can be purchased today for 20.31
-
What Is Genmab AS’s Stock Symbol?
-
When Is Genmab AS’s Next Earnings Date?The next quarterly earnings date for Genmab AS is scheduled on May 8, 2025
-
When Is GMAB's next ex-dividend date?Genmab AS's next ex-dividend date is December 22, 2024
-
How To Buy Genmab AS Stock?You can buy Genmab AS shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Genmab AS Competitors
Genmab AS Dividend Yield
Data Unavailable
Genmab AS Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | -37.41% | -12.85% |
Revenue: | 18.65% | -0.87% |
Analyst Recommendations
Buy Recommendations: | 2 |
---|---|
Hold Recommendations: | 5 |
Sell Recommendations: | 0 |
Price Target: | 36.56 |
Upside from Last Price: | 80.03% |
Major Shareholders
Data Unavailable